FDA OKs Merk Drug That Prevents Infection Post-Stem Cell Transplant
November 10, 2017
(Reuters) – Merck & Co Ltd’s drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday. Merck said the drug, which is expected to be available from December, was approved both as a tablet and an injection. The list price for the tablets is $195 per day, while it is $270 a day for the injection.The recommended dosing for the drug is once everyday for 100 days after the stem cell transplant, bringing the effective list price to $19,500 for the tablets and $27,000 for the injections.